The AIDS Healthcare Foundation (AHF) today called on Gilead Sciences and Merck to immediately register and distribute the three-in-one, once daily lifesaving HIV treatment, Atripla, in developing countries.
When Atripla first received approval from the Food and Drug Administration (FDA) in July of 2006, advocates like AHF applauded the production of a single, once-a-day drug as a landmark step in treating HIV. However, since its approval, little progress has been made in expanding the availability of the treatment in the developing world, where only 28% of those in need of treatment were able to access it as of December 2006.
"This treatment is a standard therapy in the United States.